Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference.

Cardiol Therapeutics will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12, 2025. The event will be live webcast on the company's website. The discussion will focus on the company's clinical-stage life sciences, developing anti-inflammatory and anti-fibrotic therapies for heart disease treatment.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12, 2025, in Boston, MA. The event is scheduled to commence at 9:30 a.m. EDT. Investors will have the opportunity to tune in live via the company's website, with a replay available for 90 days following the conference [1].

The discussion will delve into Cardiol Therapeutics' clinical-stage life sciences, focusing on their efforts to develop anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is currently in clinical development for this purpose [1].

CardiolRx™ is recognized for its ability to inhibit the activation of the inflammasome pathway, a process linked to inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The company has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies evaluating the efficacy and safety of CardiolRx™ in recurrent pericarditis and acute myocarditis [1].

The MAVERIC Program, which includes the completed Phase II MAVERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299), is designed to address recurrent pericarditis, an inflammatory disease of the pericardium. The ARCHER trial (NCT05180240), a Phase II study, focuses on acute myocarditis, a significant cause of acute and fulminant heart failure in young adults [1].

Cardiol Therapeutics is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure, a leading cause of death and hospitalization in the developed world [1]. The company's plans to advance the development of CRD-38 and complete the Phase III study in recurrent pericarditis with CardiolRx™ will be highlighted during the Fireside Chat [1].

For more information about Cardiol Therapeutics, please visit their website at [2].

References:
[1] https://www.newsfilecorp.com/release/261960
[2] https://www.stocktitan.net/news/CRDL/cardiol-therapeutics-to-participate-in-fireside-chat-at-canaccord-0mswgt7swtve.html